2,509,446 Shares of BridgeBio Oncology Therapeutics, Inc $BBOT Acquired by Regents of The University of California

Key Points

• Regents of the University of California acquired 2.51 million BBOT shares worth approximately $10.3 million, giving it a 3.13% stake and making BBOT its eighth-largest portfolio holding.
• Institutional investors and hedge funds own 54.89% of BBOT. Analysts maintain a consensus “Moderate Buy” rating with a $21.11 price target, despite several recent target-price reductions.
• BBOT opened at $2.69, near its 52-week low of $2.51, and reported a quarterly loss of $705.20 per share. Analysts expect a full-year loss of $2.81 per share.

Regents of The University of California acquired a new stake in BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 2,509,446 shares of the company's stock, valued at approximately $10,289,000. BridgeBio Oncology Therapeutics comprises approximately 0.2% of Regents of The University of California's portfolio, making the stock its 8th largest position. Regents of The University of California owned 3.13% of BridgeBio Oncology Therapeutics as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in BBOT. Tidal Investments LLC lifted its holdings in shares of BridgeBio Oncology Therapeutics by 13.6% in the second quarter. Tidal Investments LLC now owns 93,339 shares of the company's stock valued at $711,000 after purchasing an additional 11,167 shares in the last quarter. Tema ETFs LLC grew its position in shares of BridgeBio Oncology Therapeutics by 13.6% in the second quarter. Tema ETFs LLC now owns 93,339 shares of the company's stock valued at $711,000 after purchasing an additional 11,167 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of BridgeBio Oncology Therapeutics by 37.1% during the 1st quarter. Renaissance Technologies LLC now owns 101,900 shares of the company's stock worth $912,000 after purchasing an additional 27,600 shares in the last quarter. Avidity Partners Management LP purchased a new position in shares of BridgeBio Oncology Therapeutics during the 1st quarter worth approximately $392,000. Finally, Granahan Investment Management LLC purchased a new position in shares of BridgeBio Oncology Therapeutics during the 1st quarter worth approximately $2,068,000. 54.89% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

BBOT has been the subject of several research reports. JPMorgan Chase & Co. cut their price objective on BridgeBio Oncology Therapeutics from $25.00 to $23.00 and set an "overweight" rating for the company in a research report on Friday, September 11th. Morgan Stanley lowered their target price on BridgeBio Oncology Therapeutics to $13.00 and set an "overweight" rating on the stock in a report on Wednesday, October 21st. Stifel Nicolaus lowered their target price on BridgeBio Oncology Therapeutics from $23.00 to $15.00 and set a "buy" rating on the stock in a report on Wednesday, September 9th. UBS Group downgraded BridgeBio Oncology Therapeutics to an "overweight" rating in a research report on Wednesday, July 8th. Finally, Weiss Ratings cut BridgeBio Oncology Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, October 9th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, BridgeBio Oncology Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $21.11.

BridgeBio Oncology Therapeutics Stock Up 1.9%

BBOT stock opened at $2.69 on Wednesday. The stock has a market capitalization of $215.67 million, a price-to-earnings ratio of -0.97 and a beta of 0.65. BridgeBio Oncology Therapeutics, Inc has a 52-week low of $2.51 and a 52-week high of $14.87. The stock's fifty day simple moving average is $5.39 and its 200-day simple moving average is $8.22.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT - Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($705.20) EPS for the quarter. As a group, analysts anticipate that BridgeBio Oncology Therapeutics, Inc will post -2.81 earnings per share for the current fiscal year.

About BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with genetically driven cancers. The company is part of the broader BridgeBio platform, which supports the development of therapies for diseases linked to well-defined biological targets.

Its oncology programs are centered on small-molecule therapies intended to address cancer-causing genetic alterations, including targets that have historically been difficult to treat.

Want to see what other hedge funds are holding BBOT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.